GEO series

Generating Revitalized Stem Cell-Engineered CAR-NKT Cells for the Treatment of Malignant Pleural Mesothelioma

GSE305915 Homo sapiens (human) RNA-seq (gene expression) 1 samples Submitted 2025/08/27 Platform GPL24676

At a glance

RNA-seq (gene expression) · human · 1 samples

What it is: RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism: Homo sapiens (human)
Topic: MesotheliomaThis series is part of our curated briefing on it.
Samples: 1 samples
Data you can get: A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.

Summary (written by the submitters)

Malignant pleural mesothelioma (MPM) is a rare but highly aggressive cancer of the pleural lining, characterized by poor prognosis and limited treatment options. While mesothelin (MSLN)-targeted chimeric antigen receptor (CAR)-engineered T (MCAR-T) cell therapy has shown promise in early clinical trials, current autologous approaches are constrained by complex manufacturing processes and delayed treatment timelines, that are particularly challenging for patients with rapidly progressing MPM disease.

Read the full summary ↓

Here, we report the development of allogeneic IL-15–enhanced, MCAR-engineered invariant natural killer T (Allo15MCAR-NKT) cells, generated via hematopoietic stem and progenitor cell engineering and a clinically guided, feeder-free culture system. This platform enables the scalable production of CAR-NKT cells with high yield, purity, and clinical-grade suitability. Allo15MCAR-NKT cells exhibit potent antitumor activity in vitro and in multiple in vivo models of MPM, mediated through diverse tumor-targeting mechanisms. These cells also demonstrate a revitalized immunophenotypic profile, characterized by low expression of exhaustion markers and immune checkpoints, suggesting sustained functional potential. Importantly, the therapy exhibits a strong safety profile, with minimal signs of graft-versus-host disease (GvHD), cytokine release syndrome (CRS), or off-tumor toxicity. Collectively, this study presents a clinically translatable, off-the-shelf allogeneic CAR-NKT cell therapy with robust antitumor efficacy and a favorable safety profile for the treatment of MPM.

This dataset

Open GSE305915 in finder → Find more human RNA-seq datasets → Mesothelioma landscape →

Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE305915_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1308372 and SRA study SRP610115. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗

Samples in this study

The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.

+ 1 more — browse all 1 samples with per-sample file links →

More Mesothelioma datasets

GSE272176 PD-1 blockade mitigates surgery-induced immunosuppression and increases the efficacy of photodynamic therapy for malignant pleural mesothelioma 82 samples same disease briefing · shares mesothelioma, malignant, pleural
GSE292620 Genome-wide CRISPR Screen Identifies BUB1 Kinase as a Druggable Vulnerability in Malignant Pleural Mesothelioma 12 samples same disease briefing · shares mesothelioma, malignant, pleural
GSE270379 Deoxypodophyllotoxin suppresses Malignant pleural mesothelioma growth via mitotic dependent necroptosis 8 samples same disease briefing · shares mesothelioma, malignant, pleural
GSE51024 Gene Expression of Malignant Pleural Mesothelioma Tumor and paired Normal Lung tissue 96 samples same disease briefing · shares mesothelioma, malignant, pleural
GSE2549 Malignant pleural mesothelioma 54 samples same disease briefing · shares mesothelioma, malignant, pleural
GSE327167 Single-cell RNA-seq profiling of pleural mesothelioma and comparator pleural specimens 113 samples same disease briefing · shares mesothelioma, pleural
GSE262853 Gene expression analysis in mesothelioma cell lines with and without K-975 treatment 36 samples same disease briefing · shares mesothelioma, treatment
GSE274983 Soluble Mesothelin-Related Peptide as a Prognosticator in Pleural Mesothelioma Patients Receiving Checkpoint Immunotherapy 18 samples same disease briefing · shares mesothelioma, pleural

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.